GIFLF
Grifols, S.A. OTC$10.57
Mkt Cap $7.2B
52w Low $8.50
37.6% of range
52w High $14.00
50d MA $11.92
200d MA $12.72
P/E (TTM)
17.0x
EV/EBITDA
12.5x
P/B
1.3x
Debt/Equity
1.8x
ROE
7.6%
P/FCF
8.7x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$11.92
200d MA
$12.72
Avg Volume
1.2K
About
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent,…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.30 | 0.29 | -1.9% | 12.90 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Nov 4, 2025 | AMC | 0.24 | 0.22 | -10.8% | 13.90 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Jul 29, 2025 | AMC | 0.23 | 0.20 | -11.7% | 13.90 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| May 12, 2025 | AMC | 0.15 | 0.10 | -36.0% | 8.50 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Feb 26, 2025 | AMC | 0.23 | 0.10 | -54.4% | 10.30 | +9.7% | +9.7% | +9.7% | +9.7% | +9.7% | +9.7% | — |
| Nov 7, 2024 | AMC | 0.22 | 0.08 | -65.5% | 11.36 | +0.0% | +0.0% | +0.0% | +0.3% | +0.3% | +0.3% | — |
| Jul 30, 2024 | AMC | 0.14 | 0.02 | -85.1% | 9.51 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| May 14, 2024 | AMC | 0.11 | 0.09 | -14.4% | 10.59 | +0.0% | +0.0% | +0.0% | +5.3% | +5.3% | +5.3% | — |
| Mar 31, 2024 | AMC | — | 0.03 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | 0.20 | 0.09 | -53.9% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 4 | Deutsche Bank | Downgrade | Buy → Hold | — | $22.67 | $22.67 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Mar 22 | Credit Suisse | Upgrade | Neutral → Outperform | — | $25.80 | $25.80 | +0.0% | +0.0% | +0.0% | +1.9% | +1.9% | +1.9% |
| Mar 10 | HSBC | Upgrade | Hold → Buy | — | $23.39 | $23.24 | -0.6% | -0.6% | +5.2% | +5.2% | +5.2% | +10.3% |
| Oct 27 | Santander | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Jun 26 | JP Morgan | Upgrade | Neutral → Overweight | — | $27.77 | $27.77 | +0.0% | +0.0% | +4.1% | +4.1% | +6.8% | +6.8% |
| Feb 7 | Berenberg | Downgrade | Buy → Hold | — | $27.42 | $27.42 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Jan 1 | Morgan Stanley | Maintains | Underweight → Underweight | — | — | — | — | — | — | — | — | — |
| Sep 30 | Morgan Stanley | Maintains | Underweight → Underweight | — | — | — | — | — | — | — | — | — |
| Feb 28 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.60 | $29.60 | +0.0% | +0.0% | +0.0% | +0.0% | -7.9% | -7.9% |
| Feb 8 | Berenberg | Upgrade | Hold → Buy | — | $20.33 | $20.33 | +0.0% | +0.0% | +0.0% | +0.0% | +1.0% | +1.0% |
Data updated apr 28, 2026 9:46am
· Source: massive.com